Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 11,400 shares, a decrease of 46.0% from the October 31st total of 21,100 shares. Based on an average trading volume of 336,800 shares, the short-interest ratio is presently 0.0 days. Approximately 2.1% of the shares of the stock are sold short.
Hedge Funds Weigh In On Bluejay Diagnostics
An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP increased its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,280 shares of the company’s stock after buying an additional 249,770 shares during the quarter. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Price Performance
Shares of BJDX traded up $0.02 during trading hours on Friday, hitting $3.50. 8,284 shares of the company were exchanged, compared to its average volume of 103,749. The firm has a fifty day simple moving average of $5.18 and a 200-day simple moving average of $54.42. The company has a market capitalization of $1.89 million, a PE ratio of 0.00 and a beta of 0.73. Bluejay Diagnostics has a one year low of $3.03 and a one year high of $1,564.00.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- What is the Australian Securities Exchange (ASX)
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3 Penny Stocks Ready to Break Out in 2025
- How to Invest in the Best Canadian StocksÂ
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.